Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Surge
Pulse Biosciences (PLSE) has experienced a significant surge in its share price, with a 34.22% increase over the past week and a 91.26% year-to-date return, bringing its market value to approximately US$1.70 billion. Despite this momentum, Simply Wall St's fair value narrative suggests the stock is overvalued by 16.4% at $25.61 compared to a fair value of $22. The company's advancing clinical programs for cardiac surgical tools point to future growth, but risks related to clinical data and profitability remain.
Pulse Biosciences Begins nPulse Study for Malignant Thyroid Tumor Treatment
Pulse Biosciences has initiated a first-in-human feasibility study for its nPulse™ Vybrance Percutaneous Electrode System, aiming to treat T1N0M0 papillary thyroid microcarcinoma. The study, which has already enrolled its first patients at two sites, will evaluate the safety and effectiveness of the system for thyroid cancer tumors smaller than 1.5 cm. This technology offers a minimally invasive, non-thermal approach that could serve as an alternative to surgery or serial surveillance for low-risk thyroid cancer.
Pulse Biosciences names new CEO, reassigns former leader
Pulse Biosciences has appointed Burke Barrett as its new CEO, with former CEO Kevin Danahy transitioning to Chief Commercial Officer. Danahy will focus on launching the recently cleared Cellfx percutaneous electrode system, a pulsed field ablation device. Barrett, who has a background in ablation device development from Cardiofocus, will lead other initiatives including bringing a cardiac ablation clamp to market, which currently requires human data for FDA clearance.
Pulse Biosciences director Robert W. Duggan acquires $13m in stock
Pulse Biosciences director Robert W. Duggan purchased 660,233 shares of company stock for approximately $13 million on May 11, 2026, at $19.69 per share. The stock has since risen by nearly 25% to $24.57, with significant year-to-date and one-year returns. Duggan now directly holds over 48 million shares, with additional indirect holdings, and InvestingPro analysis suggests the stock is currently overvalued.
Pulse Biosciences director Robert W. Duggan acquires $13m in stock
Robert W. Duggan, a director at Pulse Biosciences Inc. (NASDAQ:PLSE), acquired 660,233 shares worth nearly $13 million on May 11, 2026, boosting his direct holdings to over 48 million shares. This insider purchase, along with a recent earnings beat and strong stock performance, highlights significant ongoing activities at the company despite some financial health concerns raised in its Q1 2026 report.
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares
Pulse Biosciences director Robert W. Duggan purchased 660,233 shares of common stock at $19.69 per share through an open-market transaction under the company's at-the-market equity offering program. This acquisition increased his direct holdings to over 48.3 million shares, with additional indirect holdings through wholly-owned entities. The filing also corrected a previous omission of approximately 700 shares from a Schedule 14A.
Pulse Biosciences director Robert W. Duggan acquires $13m in stock
Pulse Biosciences director Robert W. Duggan purchased 660,233 shares of the company's common stock for nearly $13 million on May 11, 2026, boosting his direct holdings to over 48 million shares. This significant insider acquisition occurred through an at-the-market offering and precedes a 25% stock value increase since the purchase. The company also recently reported better-than-expected Q1 2026 EPS and met revenue forecasts, with this director and the CEO also making similar purchases.
Pulse Biosciences stock hits 52-week high at 26.33 USD
Pulse Biosciences Inc. reached a new 52-week stock price high of $26.33, marking a significant upward trend with shares up 74.5% year-to-date and 22% in the past week. Despite this growth, InvestingPro analysis indicates the stock is currently overvalued. Co-Chairman Robert Duggan and CEO Paul LaViolette recently acquired 675,233 shares through an equity offering.
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System Study
Pulse Biosciences announced positive long-term clinical data from a study of its nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The study showed durable and significant volume reduction of treated nodules, with high patient satisfaction and no serious adverse events over 15 to 22 months. These results highlight the potential of nsPFA energy as a non-thermal treatment paradigm for this condition.
PULSE BIOSCIENCES, INC. 1Q 2026: Revenue $401K, EPS ($0.27) — 10-Q Summary
PULSE BIOSCIENCES, INC. reported Q1 2026 financial results, including product revenue of $401K and a wider net loss of ($18.58M), leading to a diluted EPS of ($0.27). The company has redirected its focus towards electrophysiology (AF) programs, reducing marketing spend on surgical and Vybrance products. Regulatory approvals and clinical progress for cardiac and surgical devices are ongoing, with positive first-in-human results for the nPulse catheter.
Pulse Biosciences (NASDAQ: PLSE) Q1 2026 results, cash burn and AF strategy
Pulse Biosciences reported a net loss of $18.6 million in Q1 2026 on modest product revenue of $0.4 million from early sales of its Vybrance Percutaneous Electrode System. The company is strategically realigning its focus and capital towards developing nsPFA electrophysiology catheters and cardiac devices for atrial fibrillation, reducing near-term spending on cardiac surgery market development and Vybrance sales. With $68.3 million in cash and an additional $12.9 million raised post-quarter, Pulse Biosciences anticipates funding operations for at least another year.
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report
Robert W. Duggan has filed Amendment No. 17 to his Schedule 13D for Pulse Biosciences, Inc. (PLSE), reporting beneficial ownership of 49,706,423 shares, representing 71.9% of the outstanding common stock. This includes shares held directly, via options, and through Genius 24C Inc and Blazon Corporation. The filing also details a recent purchase of 660,233 shares at $19.69 per share through the company’s at-the-market equity offering program.
Pulse Biosciences Insider Bought Shares Worth $12,999,988, According to a Recent SEC Filing
An insider at Pulse Biosciences recently purchased shares totaling $12,999,988, as reported in a recent SEC filing. This significant transaction provides insight into insider sentiment regarding the company's future prospects.
Pulse Bio rises after over $13M insider buying
Pulse Bio (PLSE) stock rose after reports of significant insider buying totaling over $13 million. This substantial investment by insiders suggests confidence in the company's future prospects, potentially influencing positive market sentiment.
Pulse Bio rises after over $13M insider buying
NULL
Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy
Pulse Biosciences (PLSE) stock jumped 16.8% after Co-Chairman Robert Duggan and CEO Paul LaViolette purchased a combined $13.3 million worth of shares through the company's at-the-market equity offering program. These significant insider buys, totaling 675,233 shares, signal strong internal confidence in PLSE, whose technology focuses on nanosecond pulsed field ablation for atrial fibrillation treatments. The stock is up nearly 39% year-to-date, reflecting investor interest despite mixed analyst sentiment regarding current revenues and cash burn.
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences announced that its Co-Chairmen, Robert Duggan and CEO Paul LaViolette, purchased approximately $13.3 million worth of the company's common stock through an at-the-market equity offering program. This transaction involved 675,233 shares and occurred during the company's designated trading window. Pulse Biosciences develops nPulse™ technology for non-thermal cell clearing and is exploring its use in treating atrial fibrillation and other medical applications.
Insider Buying: Paul Laviolette Acquires 15,000 Shares of Pulse Biosciences Inc (PLSE)
Paul Laviolette, CEO of Pulse Biosciences Inc (PLSE), recently purchased 15,000 shares of the company, marking his first acquisition in the past year. This transaction brought his total holdings to 15,000 shares. Insider buying and selling activities are often monitored by investors for insights into a company's prospects, with Pulse Biosciences showing two insider buys and eight insider sells over the last year.
Pulse Biosciences 10% Owner Purchased Shares Worth Over $12M
Robert W. Duggan, a 10% owner and director of Pulse Biosciences (PLSE), purchased 660,233 shares of common stock for approximately $12.99 million on May 11, 2026, at a price of $19.69 per share. Following this transaction, Duggan directly owns over 48 million shares and indirectly owns more than 1 million shares through affiliated entities. The purchase was made through the company's at-the-market equity offering program.
Pulse Biosciences director Robert Duggan buys $13 million in shares
Pulse Biosciences director Robert W. Duggan acquired 660,233 shares of common stock for nearly $13 million on May 11, 2026, as part of the company’s at-the-market equity offering program. Following this purchase, Duggan's direct holdings in Pulse Biosciences increased significantly, alongside indirect holdings through other entities. The company's stock shows high volatility according to InvestingPro, which also suggests it may be overvalued despite recent financial results indicating a positive EPS surprise.
Robert Duggan adds 660K Pulse Biosciences (PLSE) shares in open-market buy
Robert W. Duggan, a director and over 10% owner of Pulse Biosciences (PLSE), purchased 660,233 shares of common stock at $19.69 per share in an open-market transaction. This acquisition was made through the company's at-the-market equity offering program, increasing his direct holdings to 48,211,433 shares. The transaction, valued at approximately $13 million, occurred during an open trading window and in accordance with the company's insider trading policy.
[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity
PULSE BIOSCIENCES, INC. CEO Paul A. Laviollette purchased 15,000 shares of the company's common stock for $19.69 per share in an open-market transaction. This transaction was executed through the company's at-the-market equity offering program, increasing his direct ownership to 15,000 shares. The purchase occurred during an open trading window and is considered a net-buy transaction by the CEO.
Major holder controls 71.6% as Pulse Biosciences (NASDAQ: PLSE) outlines 2026 vote
Pulse Biosciences (NASDAQ: PLSE) has scheduled its 2026 virtual annual shareholder meeting for June 11, 2026, where stockholders will vote on the election of seven directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm. Robert W. Duggan, a major shareholder, controls 71.6% of the company's common stock. The company also detailed its executive compensation, director compensation, and the outcomes of its 2024 rights offering, which raised $60 million.
Number of shareholders of Pulse Biosciences, Inc – NASDAQ:PLSE
This article provides a listing for Pulse Biosciences, Inc (NASDAQ:PLSE) on TradingView, detailing its financial overview, shareholder information by period, and other market data. The content is primarily a data placeholder, indicating the availability of shareholder numbers.
Pulse Biosciences (NASDAQ: PLSE) CEO adds 15,000 shares in open-market buy
Pulse Biosciences CEO Paul A. LAVIOLETTE purchased 15,000 shares of common stock on May 11, 2026, at $19.69 per share through an open-market transaction, increasing his direct ownership to 15,846 shares. This acquisition was part of the company's at-the-market equity offering program and occurred during an open trading window. His total holdings also include shares bought via the Employee Stock Purchase Plan in March 2026.
Pulse Biosciences (PLSE) upgraded to buy: What does it mean for the stock?
The article reports that Pulse Biosciences (PLSE) has received an upgrade to "buy" from analysts. It discusses the potential implications of this upgrade for the company's stock performance. The content, however, is incomplete, primarily consisting of only the title and a mention of MSN.
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
Pulse Biosciences, Inc. has announced the appointment of Jon Skinner as its new Chief Financial Officer. This announcement was made via a press release highlighted by Quantisnow, a platform that provides real-time market data and news. The information was delivered to Quantisnow Plus members seconds after its publication.
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences announced its participation in the BofA Securities 2026 Healthcare Conference, where its management will present on Wednesday, May 13, at 4:35 pm PT. The company, known for its nPulse™ technology, is focused on developing treatments for atrial fibrillation and other medical areas. A live and recorded webcast of the presentation will be available on their investor relations website.
Earnings call transcript: Pulse Biosciences Q1 2026 EPS beats, stock drops
Pulse Biosciences (PLSE) reported mixed Q1 2026 results, with an EPS beat but a significant stock drop due to investor concerns over widening losses and increased operating expenses. The company highlighted strategic advancements in its nanosecond pulsed field ablation (nsPFA) technology, particularly for atrial fibrillation, with robust clinical trial data and accelerated enrollment timelines for its U.S. IDE pivotal study. They also provided updates on their surgical ablation clamp and nPulse Vybrance percutaneous electrode system, aiming for long-term value creation despite ongoing financial challenges.
Pulse Biosciences (Nasdaq:PLSE) - Stock Analysis
Pulse Biosciences, Inc. (PLSE) is a bioelectric medicine company focused on nanosecond pulsed field ablation (nsPFA) technology. The company has a market cap of US$1.3 billion but is currently unprofitable and not expected to break even in the near future. Recent developments include progress in pivotal cardiac ablation trials with its nPulse Cardiac Catheter System for atrial fibrillation, positive clinical data presentations, and strategic management appointments to accelerate its cardiac catheter program, alongside ongoing work in thyroid nodule treatment.
Pulse Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Pulse Biosciences Inc (PLSE) has released its earnings summary for the quarter that ended on March 31. This brief report, provided by Refinitiv, gives an overview of the company's financial performance. Investors can access more detailed information by logging in or creating an account.
Pulse Biosciences board approves affiliate participation in equity sales program
Pulse Biosciences' Board of Directors has approved its affiliates to purchase common stock through an existing Equity Distribution Agreement with TD Securities (USA) LLC. Co-Chairman Robert Duggan and CEO Paul LaViolette have indicated their likelihood to purchase shares without a discount to market price. This decision is based on a recent SEC filing and comes alongside other company developments including progress in cardiac catheter studies and leadership changes.
Pulse Biosciences board approves affiliate participation in equity sales program
Pulse Biosciences' Board of Directors has approved affiliates of the company, including Co-Chairman Robert Duggan and CEO Paul LaViolette, to purchase common stock through its existing Equity Distribution Agreement with TD Securities (USA) LLC. These purchases will be at market price, with no discount. This move follows other recent developments at Pulse Biosciences, including patient enrollment in key clinical trials and leadership changes, reflecting the company's focus on advancing its cardiac catheter program.
Major holder in Pulse Biosciences (PLSE) eyes buys under $59.98M ATM
Pulse Biosciences has announced that its Board of Directors has approved resolutions allowing affiliates, including major shareholder Robert Duggan and CEO Paul LaViolette, to purchase common stock through an existing $59.98 million at-the-market (ATM) offering. While Duggan (who beneficially owns 72% of outstanding common stock) and LaViolette have indicated they are likely to buy shares in the near term, no binding commitments or specific amounts have been disclosed. These purchases would occur at the prevailing market trading price without a discount.
Pulse Biosciences Releases Q1 2026 Financial Results
Pulse Biosciences reported a loss of $0.27 per share for Q1 2026, widening from the previous year, as the company continues to invest in its Nano-Pulse Stimulation technology. They generated $401,000 in revenue with a net loss of $18.6 million, reflecting their ongoing development stage as they work towards commercializing their CellFX System. The increased loss per share indicates higher operational spending typical for companies advancing clinical programs and preparing for market launches.
Pulse Biosciences, Inc (PLSE) reports Q1 loss, lags revenue estimates
Pulse Biosciences, Inc. (PLSE) reported a Q1 loss, missing revenue estimates. The company's financial performance data for the first quarter included an earnings per share (EPS) forecast, actual EPS, and actual revenue.
Pulse Biosciences Releases Q1 2026 Financial Results
Pulse Biosciences (PLSE) reported a Q1 2026 loss of $0.27 per share, an increase from $0.25 in Q1 2025, with revenues at $401,000 and a net loss of $18.6 million. The medical technology company's results reflect its ongoing development of the Nano-Pulse Stimulation technology and commercialization of its CellFX System, leading to increased operational spending typical for companies in this phase. The expanding loss per share is attributed to investments in clinical programs and preparations for market launches in the medical aesthetics and therapeutic space.
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences announced business updates and financial results for the first quarter ended March 31, 2026, highlighting significant progress in its nPulse Cardiac Catheter System for AF ablation, including accelerated enrollment in its U.S. IDE pivotal trial. The company reported $0.4 million in revenue, a GAAP net loss of ($18.6) million, and cash and cash equivalents totaling $68.3 million as of March 31, 2026. Key leadership additions and ongoing surgical AF ablation and soft tissue ablation programs were also noted.
Pulse Biosciences 1Q Loss/Shr 27c >PLSE
Pulse Biosciences reported a loss per share of 27 cents for the first quarter. This financial update is a key metric for investors tracking the company's performance.
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Pullback And Ongoing Losses
Pulse Biosciences (PLSE) has experienced a recent share price pullback despite significant long-term gains, operating in bioelectric medicine with a focus on its nPulse Nanosecond Pulsed Field Ablation platform. The company, valued at US$1.42 billion, reported US$0.35 million in revenue but a US$72.78 million net loss, leading to a mixed valuation outlook. While a narrative suggests it's 5.3% undervalued at $22 based on future growth expectations, its high price-to-book ratio compared to industry peers highlights concerns for a company with limited revenue and ongoing losses.
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences announced its first-quarter 2026 financial results and provided significant business updates, including accelerating enrollment for its NANOPULSE-AF cardiac catheter IDE trial to early Q4 2026 due to promising clinical outcomes and high investigator enthusiasm. The company reported $0.4 million in revenue for the quarter and a GAAP net loss of $18.6 million, with cash and cash equivalents totaling $68.3 million. Pulse Biosciences is strategically prioritizing electrophysiology, expanding its leadership team, and progressing other clinical studies using its proprietary nanosecond PFA technology.
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q1 Revenue $401,000, vs. FactSet Est of $250,000
Pulse Biosciences, Inc. (PLSE) reported first-quarter revenue of $401,000, significantly exceeding the FactSet estimate of $250,000. The company specializes in bioelectric medicine with its proprietary CellFX nsPFA technology, which focuses on non-thermally clearing cells while sparing adjacent noncellular tissue. This technology is being developed for applications in cardiology, including the treatment of atrial fibrillation, and other medical specialties.
Pulse Biosciences Inc expected to post a loss of 31 cents a share - Earnings Preview
Pulse Biosciences Inc. (PLSE) is anticipated to report a loss of 31 cents per share, according to this earnings preview. The article details the company's expected financial performance.
Earnings Flash (PLSE) Pulse Biosciences Posts Q1 Loss $0.27 a Share, vs. FactSet Est of $0.32 Loss
Pulse Biosciences (PLSE) reported a Q1 loss of $0.27 per share, which is better than the FactSet estimate of a $0.32 loss. This financial update indicates the company's performance for the first quarter.
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences announced its Q1 2026 financial results and provided business updates. The company highlighted strategic progress in its Nanosecond Pulsed Field Ablation (nsPFA™) technology, particularly for cardiac ablation procedures, and reported a total revenue of $0.3 million for the quarter. They also detailed ongoing clinical studies for various applications and discussed financial performance, including a net loss of $18.5 million.
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences announced business updates and financial results for the first quarter ended March 31, 2026, highlighting accelerated enrollment in the NANOPULSE-AF U.S. IDE pivotal clinical trial for its nPulse Cardiac Catheter System. The company reported $0.4 million in total revenue and a GAAP net loss of ($18.6) million for the quarter. Strategic focus on electrophysiology was emphasized, with key leadership additions and positive clinical data presentations supporting the nPulse technology.
Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday
Pulse Biosciences (PLSE) is anticipated to release its Q1 2026 earnings on Thursday, May 7th, with analysts projecting an EPS of ($0.32) and revenue of $0.40 million. Insider selling has occurred recently, with 85,000 shares sold in the last 90 days, though corporate insiders still own a significant 74.60% of the stock. Shares are trading around $20, and the company has a "Hold" consensus rating from analysts with an average target price of $30.00.
Executive pay and 71% insider stake at Pulse Biosciences (NASDAQ: PLSE)
Pulse Biosciences (PLSE) filed an amended annual report (10-K/A) detailing executive compensation, board composition, and governance, including significant insider ownership. CEO Paul A. LaViolette's 2025 compensation was approximately $7.4 million, largely equity-based with performance and market-driven vesting conditions, while CFO Jon Skinner received about $2.8 million. Director Robert W. Duggan beneficially owns 71.6% of outstanding common stock, with all directors and executive officers collectively holding 74.7%, indicating highly concentrated ownership.
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.9% - What's Next?
Pulse Biosciences (NASDAQ:PLSE) experienced a 7.9% drop in share price on Wednesday, trading at $20.11 with significantly lower-than-average volume. Despite this, the company's market cap remains around $1.37 billion, and it beat recent quarterly EPS estimates. While analysts are mixed, the consensus rating is "Hold" with an average price target of $30.
New nPulse atrial fibrillation data for Pulse Biosciences (NASDAQ: PLSE)
Pulse Biosciences (NASDAQ: PLSE) reported positive updated results from its first-in-human clinical study of the nPulse Cardiac Catheter System for atrial fibrillation. The data showed high procedural success rates of 100% at 6 months and 96% at one year, with a 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year. The study also highlighted efficient procedure times and a low serious adverse event rate of 1.7%, indicating strong durability and safety for their non-thermal nsPFA approach.
